NIH Clinical Research Studies Listed By Institute of the Principal Investigator

National Cancer Institute (NCI)

342 Protocols (232 Active Accrual of new subjects, 110 Follow-up of previously enrolled subjects)

Active Accrual, Protocols Recruiting New Patients 
* 10-C-0021:
A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults with Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

* 10-C-0011:
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

* 09-C-0243:
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors

* 09-C-0242:
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

* 09-C-0224:
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

* 09-C-0222:
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination with Carboplatin versus Carboplatin Alone Followed by Vandetanib Alone in Adults with Recurrent High-Grade Gliomas

* 09-C-0214:
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)

* 09-C-0212:
Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma who have been Previously Treated with Chemotherapy

* 09-C-0210:
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

* 09-C-0195:
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

* 09-C-0192:
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

* 09-C-0189:
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial

* 09-C-0174:
M06-822: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer or Other Non-Hematological Malignancies

* 09-C-0173:
A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with Small Cell Lung Carcinoma and Other Advanced Cancers

* 09-C-0168:
A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects with Relapsed or Refractory Solid Tumors Associated with EphA2 Expression

* 09-C-0161:
Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies

* 09-C-0139:
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

* 09-C-0138:
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocelluar and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors

* 09-C-0130:
Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab Followed by Bevacizumab Monotherapy in Adults with Advanced Kaposi's Sarcoma

* 09-C-0127:
Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial

* 09-C-0120:
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

* 09-C-0113:
A Pilot Study to Explore Serum and Imaging Biomarkers in Patients with Spinal Cord Compression

* 09-C-0112:
A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies

* 09-C-0111:
A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies

* 09-C-0107:
Phase II Study of Neoadjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2), Non-Squamous Cell Non-Small Cell Lung Cancer

* 09-C-0104:
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZDO53O, a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung

* 09-C-0103:
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

* 09-C-0101:
Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults with Metastatic CEA-Expressing Carcinoma

* 09-C-0100:
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy

* 09-C-0096:
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

* 09-C-0092:
Phase 1/2 Study of Metastatic Renal Cancer using T-Cells Transduced with a T-Cell Receptor which Recognizes TRAIL Bound to the DR4 Receptor

* 09-C-0089:
A Targeted Ph I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (M

* 09-C-0082:
Phase I/II Study of B Cell Malignancies using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer

* 09-C-0080:
A Phase 2, Open-label, Proof-of-Concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of Alpha v Beta 3 Integrin Receptors by (18F)AH-111585 PET Imaging

* 09-C-0079:
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)

* 09-C-0077:
An Open-Label Clinical Trial of MORAb-009 in Combination with Pemetrexed and Cisplatin in Subjects with Mesothelioma

* 09-C-0076:
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

* 09-C-0072:
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas with Botulinum Toxin

* 09-C-0065:
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas

* 09-C-0057:
A Phase II Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma

* 09-C-0054:
A Group Wide Biology and Banking Study for Phase II Study of R1507

* 09-C-0053:
Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)

* 09-C-0052:
Informed Consent in Pediatric Phase I Cancer Trials

* 09-C-0051:
Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines

* 09-C-0048:
A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

* 09-C-0047:
Phase I/II Study of Metastatic Cancer that Expresses Carcinoembryonic Antigen (CEA) using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes

* 09-C-0037:
A Phase II Clinical Trial of Ixabepilone (Ixempra, BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer

* 09-C-0025:
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

* 09-C-0024:
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults

* 09-C-0019:
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors

* 09-C-0018:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Adults with Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Two or More Prior Treatment Regimens

* 09-C-0005:
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease

* 09-C-0003:
A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Adults with Advanced Malignancies and Varying Degrees of Liver Dysfunction

* 08-C-0226:
A Pilot Study of 11C-Acetate Positron Emission Tomography (PET) and 3 Telsa Magnetic Resonance Imaging (MRI) in Men with Prostate Cancer Undergoing Prostatectomy

* 08-C-0214:
A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases

* 08-C-0208:
Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer

* 08-C-0200:
A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma

* 08-C-0180:
Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

* 08-C-0179:
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children with Refractory Solid Tumors

* 08-C-0176:
First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Etoposide, Doxorubicin, Cisplatin and Mitotane vs Streptozotocin and Mitotane

* 08-C-0168:
A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas

* 08-C-0166:
An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults with Non-Small Cell Lung Cancer (NSCLC)

* 08-C-0164:
A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-cell Lymphoma Following Prior Systemic Therapy

* 08-C-0162:
Transfer of Autologous T Cells Transduced with the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma

* 08-C-0151:
A Pilot Study of Sirolimus (Rapamycin, Rapammune[Registered Trademark]) in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

* 08-C-0148:
A Pilot Study of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease

* 08-C-0130:
A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas

* 08-C-0128:
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors

* 08-C-0123:
A Phase 1, Multi-Center, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (pALL) or Non-Hodgkin's Lymphoma (NHL)

* 08-C-0121:
Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes

* 08-C-0104:
Phase II Study in Patients with Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin

* 08-C-0101:
A Phase 2 Trial of Tandutinib in Combination with Bevacizumab for Patients with Recurrent High-Grade Gliomas

* 08-C-0097:
Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults

* 08-C-0096:
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas

* 08-C-0092:
A Phase I Study with an Expansion Cohort of the PARP Inhibitor AZD2281 Combined with Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer

* 08-C-0091:
Phase I Study of SNX-5422 Mesylate in Adults with Refractory Solid Tumor Malignancies and Lymphomas

* 08-C-0088:
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells

* 08-C-0087:
Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults with Solid Tumors and Lymphomas

* 08-C-0086:
A Phase 2, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regime and Failure of Prior Treatment with Erlotinib

* 08-C-0083:
Registration Ph III Study of Lucanix (Trademark) in Adv NSC Lung Cancer: An Intl Mltctr RDBPC Study of Lucanix(Trademark) Maint Ther for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Dx Following One Reg of Front-line, Platinum-based

* 08-C-0080:
SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the IGF-1 Receptor for the Treatment of Patients with Recurrent or Refractory Ewing's Sarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas

* 08-C-0079:
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1

* 08-C-0078:
A Phase I/II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined with Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects with Relapsed or Refractory NSCLC whose Tumors bear Activation of mTOR

* 08-C-0075:
Phase III Evaluation of Recombinant MAGE-A3 Vaccine as Adjuvant Therapy Following Resection of MAGE-A3-Positive Non-Small Cell Lung Cancer

* 08-C-0074:
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)

* 08-C-0056:
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization

* 08-C-0055:
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization

* 08-C-0051:
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies

* 08-C-0033:
A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma

* 08-C-0030:
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

* 08-C-0026:
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma

* 08-C-0020:
A Phase 2 Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors

* 08-C-0015:
A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas

* 08-C-0007:
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer

* 07-C-0230:
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases

* 07-C-0220:
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors

* 07-C-0210:
Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma

* 07-C-0206:
A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients with High Risk Pediatric Solid Tumors

* 07-C-0203:
A Phase I Study of ABT-888 in Combination with Topotecan Hydrochloride in Adults with Refractory Solid Tumors and Lymphomas

* 07-C-0195:
Pilot Trial of Targeted Immune-Depleting Chemo & Reduced-Intensity Allo Hematopoietic SCT Using 8/8 & 7/8 HLA-Matched Unrelated Donors and Utilizing 2 GVHD Prophy Regimens for the Tx of Leukemias, Lymphomas, & Pre-Malignant Blood Disorders

Next 100 Protocols

Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Clinical Center LogoNational Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 11/25/2009
Search The Studies Help Questions
Search The Studies Help Questions